New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
08:06 EDTGENEGenetic Technologies downgraded to Sell from Buy at Ladenburg
Ladenburg downgraded Genetic Technologies two notches to Sell based on concerns it will not be able to secure patent license agreements due to the current patent landscape following the Mayo v Prometheus decision and the July 2012 USPTO decision to reexamination GENE’s ‘179 patent. As a result, the firm sees limited revenue contribution from its pipeline near-term. Price target cut to $1.60 from $7.50.
News For GENE From The Last 14 Days
Check below for free stories on GENE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2014
08:47 EDTGENEGenetic Technologies says NC court denies GlaxoSmithKline motion to dismiss
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use